Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 101–200 of 1,000
Lou, X., Tang, Y., Ye, L., Pretorius, D., Fast, V. G., Kahn-Krell, A. M., Zhang, J., Zhang, J., Qiao, A., Qin, G., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad004 · Cited by 51
Fibroblasts—Warriors at the Intersection of Wound Healing and Disrepair
Roman, J. (2023) · Biomolecules · doi:10.3390/biom13060945 · Cited by 55
“Excessive TGFβ production may lead to fibrosis in the liver, kidneys, and heart [44,56,57].”
BackgroundWang, B., Tan, Y., Zhang, Y., Zhang, S., Duan, X., Jiang, Y., Li, T., Zhou, Q., Liu, X., & Zhan, Z. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00904-y · Cited by 48
Circular RNAs in Cardiovascular Diseases: Regulation and Therapeutic Applications
Wang, L., Xu, G.-E., Spanos, M., Li, G., Lei, Z., Sluijter, J. P. G., & Xiao, J. (2023) · Research · doi:10.34133/research.0038 · Cited by 54
Quercetin and dasatinib, two powerful senolytics in age-related cardiovascular disease
Nieto, M., Königsberg, M., & Silva‐Palacios, A. (2023) · Biogerontology · doi:10.1007/s10522-023-10068-5 · Cited by 53
Heart failure, inflammation and exercise
Luo, Q., Zhang, Q., Kong, Y., Wang, S., & Quan, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.109917 · Cited by 50
Lu, L., Ma, J., Yang, L., Shao, Y., Xiong, X., Duan, W., Gao, E., Yang, Q., Chen, S., Yang, J. Z., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.757068 · Cited by 49
“Myocardial infarction (MI) is one of the major cardiac sequelae in patients with DM, accompanied by mitochondrial dysfunction, inflammation, apoptosis, and myocardial fibrosis (Birnbaum et al., 2019; Lu et al., 2020a; Frangogiannis 2020; Wu et al., 2021).”
BackgroundA heart-brain-spleen axis controls cardiac remodeling to hypertensive stress
Perrotta, S., Carnevale, L., Perrotta, M., Pallante, F., Mikolajczyk, T. P., Fardella, V., Migliaccio, A., Fardella, S., Nejat, S., Kapelak, B., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.013 · Cited by 48
Arrhythmogenic Remodeling in the Failing Heart
Husti, Z., Varró, A., & Baczkó, I. (2021) · Cells · doi:10.3390/cells10113203 · Cited by 49
“In addition, impulse conduction can be impaired due to fibrosis and scars (Figure 1A) observed in HF [13].”
BackgroundFang, J., Zhang, Y., Chen, D., Zheng, Y., & Jiang, J. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s377479 · Cited by 48
“Interstitial fibrosis and perivascular fibrosis, stimulated by persistent maladaptive factors, are characterized by the diffuse ECM deposition and fibrosis formation in the myocardial interstitium or around the cardiac capillary.(18,19)”
BackgroundLi, X., Mu, B., Li, X., & Bie, Z. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10209-0 · Cited by 46
Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues
Dooling, L. J., Saini, K., Anlaş, A. A., & Discher, D. E. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.006 · Cited by 46
Liu, Y., Wang, S., Zhang, J., Sun, Q., Xiao, Y., Chen, J., Yao, M., Zhang, G., Huang, Q., Zhao, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50854-4 · Cited by 46
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 59
Zheng, D., Chen, L., Li, G., Jin, L., Wei, Q., Liu, Z., Yang, G., Li, Y., & Xie, X. (2022) · Food & Function · doi:10.1039/d2fo01761j · Cited by 45
Werbner, B., Tavakoli‐Rouzbehani, O. M., Fatahian, A. N., & Boudina, S. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.42 · Cited by 53
Ku, J. C., Raiten, J., & Li, Y. (2024) · Biomedical Engineering Advances · doi:10.1016/j.bea.2024.100118 · Cited by 49
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
Chen, B., Guo, J., Ye, H., Wang, X., & Feng, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13197 · Cited by 48
Bai, B., Cheng, M., Jiang, L., Xu, J., Chen, H., & Xu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.614757 · Cited by 46
Lai, Q., Liu, F., Rao, W.-L., Yuan, G., Fan, Z., Zhang, L., Fu, F., Kou, J., Yu, B., & Li, F. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00830-1 · Cited by 44
“Cardiac fibroblasts undergo conversion to myofibroblasts in infarcted hearts, which is the crucial cellular event in myocardial fibrosis [55].”
BackgroundLi, J., Liao, R., Zhang, S., Weng, H., Liu, Y., Tao, T., Yu, F., Li, G., & Wu, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154867 · Cited by 46
Zheng, X., Liu, L., Liu, J., Zhang, C., Zhang, J., Qi, Y., Xie, L., Zhang, C., Yao, G., & Bu, P. (2023) · Advanced Science · doi:10.1002/advs.202207631 · Cited by 44
Aghagolzadeh, P., Plaisance, I., Bernasconi, R., Treibel, T. A., Pulido-Quetglas, C., Wyss, T., Wigger, L., Nemir, M., Sarre, A., Chouvardas, P., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062601 · Cited by 46
Phosphodiesterase in heart and vessels: from physiology to diseases
Fu, Q., Wang, Y., Chen, Y., & Xiang, Y. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00015.2023 · Cited by 50
Di, X., Chen, J., Li, Y., Wang, M., Wei, J., Li, T., Liao, B., & Luo, D. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1545 · Cited by 46
“36 Fibrosis is a highly orchestrated process that includes multiple cellular responses and signalling cascades.”
BackgroundHeart-on-a-chip systems: disease modeling and drug screening applications
Butler, D., & Reyes, D. R. (2024) · Lab on a Chip · doi:10.1039/d3lc00829k · Cited by 47
Complex regulation of cardiac fibrosis: insights from immune cells and signaling pathways
Rao, W., Li, D., Zhang, Q., Liu, T., Gu, Z., Huang, L., Dai, J., Wang, J., & Hou, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06260-5 · Cited by 45
Zhang, Y., Cao, Y., Zheng, R., Xiong, Z., Zhu, Z., Gao, F., Man, W., Duan, Y., Lin, J. M., Zhang, X., et al. (2022) · Theranostics · doi:10.7150/thno.77043 · Cited by 46
Nemtsova, V. D., Vischer, A. S., & Burkard, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072606 · Cited by 51
“) reduce the collagen content and LV stiffness in hypertensive patients regardless of their blood pressure-lowering effect [30,33,51,74].”
BackgroundInfluentialRedox homeostasis in cardiac fibrosis: Focus on metal ion metabolism
Liu, Z., Liu, Z., Lin, L.-C., Song, K., Tu, B., Ye, Z., Yang, J., Zhao, J., & Tao, H. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103109 · Cited by 43
“Reactive fibrosis, on the other hand, is usually caused by excessive accumulation of ECM proteins [5], often without significant loss of myocardial cells, and is mainly seen in hypertensive patients, primarily occurring around the cardiac vessels [6].”
BackgroundThe Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
Cunha, P. S., Laranjo, S. M., Heijman, J., & Oliveira, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.879984 · Cited by 44
“The term ‘perivascular fibrosis’ is used to describe the expansion of the microvascular adventitia (46).”
BackgroundRoles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis
Shao, J., Liu, J., & Zuo, S. (2022) · Cells · doi:10.3390/cells11152347 · Cited by 42
Liu, M., Long, X., Xu, J., Chen, M., Yang, H., Guo, X., Kang, J., Ouyang, Y., Luo, G., Yang, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106515 · Cited by 42
Frangogiannis, N. G. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2316735 · Cited by 42
“Regardless of the primary etiology, most forms of heart failure are associated with myocardial fibrosis, the expansion of the cardiac interstitium due to extracellular matrix (ECM) deposition [4].”
BackgroundSelf-citationLiu, Y., Huang, X., Wang, Z., Guo, Z., Ma, C., Li, D., Luo, Y., Hu, X., Chen, F., & Li, D. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157272 · Cited by 43
CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure
Zhang, Y., Ye, Y., Tang, X., Wang, H., Tanaka, T., Tian, R., Yang, X., Wang, L., Xiao, Y., Hu, X., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20200418 · Cited by 44
“It has been verified in both clinical cohort (Rosello-Lleti et al., 2007) and animal model (Frangogiannis, 2021; Peng et al., 2015) studies that the Th2 cytokine IL-4 participates in HF progression by promoting myocardial fibrosis.”
BackgroundResultProgress on role of ion channels of cardiac fibroblasts in fibrosis
Xing, C., Bao, L., Li, W., & Fan, H. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1138306 · Cited by 41
“The main function of fibroblasts is to synthesize structural proteins, including ECM proteins, and maintain the homeostasis of ECM through the synthesis and degradation of connective tissue components (Frangogiannis, 2021; Frangogiannis, 2022).”
BackgroundLoss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease
Weyrich, M., Cremer, S., Gerster, M., Sarakpi, T., Rasper, T., Zewinger, S., Patyna, S., Leistner, D. M., Heine, G. H., Wanner, C., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069139 · Cited by 41
Zhao, Y., Du, D., Chen, S., Chen, Z., & Zhao, J. (2022) · Genes · doi:10.3390/genes13081390 · Cited by 42
Pathophysiological Roles of the TRPV4 Channel in the Heart
Chaigne, S., Barbeau, S., Ducret, T., Guinamard, R., & Benoîst, D. (2023) · Cells · doi:10.3390/cells12121654 · Cited by 41
“Finally, the link between fibrosis and the increased risk for atrial [51,170–172] or ventricular [115] arrhythmias has been reported in several cardiac diseases [167,173].”
BackgroundInhibition of HSP90 S‐nitrosylation alleviates cardiac fibrosis via TGFβ/SMAD3 signalling pathway
Zhang, X., Zhang, Y., Qing, M., Shi, Z., Hu, L., Liu, S., Gao, J., Zhao, S., Chen, H., Huang, Z., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15626 · Cited by 41
Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis
Yang, B., Qiao, Y., Dong, Y., & Meng, Q. (2024) · Cells · doi:10.3390/cells13090764 · Cited by 42
“Cells 2024 , 13 , x FOR PEER REVIEW 2 of 20 differentiation of cardiac fibroblasts (CFs) [6].”
BackgroundMa, H., Wu, K., Dong, F.-H., Cai, B., Wu, D., & Lu, H.-Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-80829-w · Cited by 41
“It hyper-activates the body’s reparative mechanisms, leading to cardiac remodeling, as outlined by Frangogiannis 5 .”
Cardiac fibroblasts in myocardial injury and heart failure
Linthout, S. V., Matz, I., González, A., & Davis, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf902 · Cited by 47
Munguía-Galaviz, F. J., Miranda‐Díaz, A. G., Cárdenas-Sosa, M. A., & Echavarría, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031997 · Cited by 42
“Fibrosis is a pathophysiological partner of CVDs as chronic injury continually activates myofibroblasts and promotes extracellular matrix buildup to develop scar tissue [185].”
BackgroundLi, X., Li, R., You, N., Zhao, X., Li, J., & Jiang, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.875473 · Cited by 46
“MF might reflect the activation of repair or maladaptive processes (5).”
BackgroundRNA-binding proteins in cardiovascular biology and disease: the beat goes on
Völkers, M., Preiß, T., & Hentze, M. W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00958-z · Cited by 40
“Heart failure is characterized by extensive fibrosis, independently of the aetiology 187 .”
Torimoto, K., Elliott, K., Nakayama, Y., Yanagisawa, H., & Eguchi, S. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae044 · Cited by 38
The isoproterenol-induced myocardial fibrosis: A biochemical and histological investigation
Flori, L., Lazzarini, G., Spezzini, J., Pirone, A., Calderone, V., Testai, L., & Miragliotta, V. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116534 · Cited by 41
Inhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development
Khalaji, A., Mehrtabar, S., Jabraeilipour, A., Doustar, N., Youshanlouei, H. R., Tahavvori, A., Fattahi, P., Alavi, S. M. A., Taha, S. R., Naghibi, A. F., et al. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241253134 · Cited by 38
Adult cardiomyocytes‐derived EVs for the treatment of cardiac fibrosis
Prieto‐Vila, M., Yoshioka, Y., Kuriyama, N., Okamura, A., Yamamoto, Y., Muranaka, A., & Ochiya, T. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12461 · Cited by 38
The harder the climb the better the view: The impact of substrate stiffness on cardiomyocyte fate
Querceto, S., Santoro, R., Gowran, A., Grandinetti, B., Pompilio, G., Regnier, M., Tesi, C., Poggesi, C., Ferrantini, C., & Pioner, J. M. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.02.001 · Cited by 39
“Indeed, in pathological conditions it is observed that a progressive increase of tissue stiffness is responsible for a dysfunctional and fibrotic myocardium [5].”
BackgroundInfluentialRole of Ferroptosis in Fibrotic Diseases
Zhou, J., Tan, Y., Wang, R., & Li, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s358470 · Cited by 40
“Cardiac fibrosis is thought to play crucial roles in cardiac remodeling, which is closely associated with heart failure.(88) Moreover, ferroptosis is enhanced in heart failure.”
BackgroundLiu, J., Lu, J., Zhang, L., Liu, Y., Zhang, Y., Gao, Y., Yuan, X., Xiang, M., & Tang, Q. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114080 · Cited by 41
Ren, C., Zhao, X., Liu, K., Wang, L., Chen, Q., Jiang, H., Gao, X., Lv, X., Zhi, X., Wu, X. S., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.116128 · Cited by 41
Yoshida, S., Yoshida, T., Inukai, K., Kato, K., Yura, Y., Hattori, T., Enomoto, A., Ohashi, K., Okumura, T., Ouchi, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52068-0 · Cited by 37
Late gadolinium enhancement imaging and sudden cardiac death
Prasad, S. K., Akbari, T., Bishop, M. J., Halliday, B. P., Leyva, F., & Marchlinski, F. E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf464 · Cited by 38
Microparticle Mediated Delivery of Apelin Improves Heart Function in Post Myocardial Infarction Mice
Tang, L. F. P., Qiu, H., Xu, B., Su, Y., Nyarige, V., Li, P., Chen, H., Killham, B., Liao, J., Adám, H., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324608 · Cited by 37
Yang, P., Zhu, L., Wang, S., Gong, J., Selvaraj, J. N., Ye, L., Chen, H., Zhang, Y., Wang, G., Song, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52221-9 · Cited by 40
Epitranscriptomic regulation of cardiac fibrosis via YTHDF1-dependent PIEZO2 mRNA m6A modification
Ding, J.-F., Tu, B., Song, K., Liu, Z., Lin, L.-C., Liu, Z., Shi, Y., Yang, J.-J., Zhao, J., & Tao, H. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae239 · Cited by 39
Gut microbiota and myocardial fibrosis
Han, X., Yang, F., & Bao, Z. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175355 · Cited by 37
Fang, R., Zhou, R., Ju, D., Mi, L., Wang, H., Pan, L., Wang, X., Man, H., & Yu, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155719 · Cited by 35
Bakhshi, H., Michelhaugh, S. A., Bruce, S. A., Seliger, S. L., Qian, X., Ambale‐Venkatesh, B., Varadarajan, V., Bagchi, P., Lima, J. A. C., & deFilippi, C. R. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104490 · Cited by 35
Engineered cardiac tissue model of restrictive cardiomyopathy for drug discovery
Wang, B. Z., Nash, T. R., Zhang, X., Rao, J., Abriola, L., Kim, Y., Zakharov, S. I., Kim, M., Luo, L. J., Morsink, M. A. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100976 · Cited by 36
“Lastly, the contribution of non-myocyte cells to cardiac disease is becoming increasingly recognized.(48,49) The expression of FLNC, though highest in cardiomyocytes, is not exclusive to cardiomyocytes (Heart Cell Atlas).”
BackgroundSystems Biology in Chronic Heart Failure—Identification of Potential miRNA Regulators
Vilella-Figuerola, A., Gallinat, A., Escate, R., Mirabet, S., Padró, T., & Badimón, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315226 · Cited by 36
Circular RNA regulatory role in pathological cardiac remodelling
Bibi, A., Barteková, M., Gandhi, S., Greco, S., Madè, A., Sarkar, M., Stopa, V., Tastsoglou, S., de Gonzalo‐Calvo, D., Devaux, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16434 · Cited by 36
“…relieved the apoptotic and inflammatory injury induced by H/R, and this effect was mediated by miR-622 repression and induction of its target, the anti-apoptotic Bcl-2 family member MCL1 (Wang, Cheng, et al., 2021). growth factor (PDGF) and cytokines (Frangogiannis, 2021; Schirone et al., 2022).”
Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
Rolski, F., & Ma̧czewski, M. (2025) · Pharmaceuticals · doi:10.3390/ph18030313 · Cited by 37
“Cardiac fibrosis is a pathological condition characterized by the excessive deposition of extracellular matrix (ECM) components, such as collagen, in the heart tissue, leading to stiffening and impaired cardiac function [3].”
Exercise training attenuates angiotensin II-induced cardiac fibrosis by reducing POU2F1 expression
Feng, N., Yu, H., Wang, Y., Zhang, Y., Han, X., & Gao, W. D. (2022) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2022.10.004 · Cited by 36
Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension
Bekedam, F. T., Goumans, M., Bogaard, H. J., de Man, F. S., & Valldeperas, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108389 · Cited by 34
Wang, M., Wang, M., Zhao, J., Xu, H., Xi, Y., & Yang, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154849 · Cited by 34
Review: Acetylation mechanisms and targeted therapies in cardiac fibrosis
Liu, W., Yuan, Q., Cao, S., Wang, G., Liu, X., Xia, Y., Bian, Y., Xu, F., & Chen, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106815 · Cited by 35
circRNA-miRNA-mRNA Deregulated Network in Ischemic Heart Failure Patients
Madè, A., Bibi, A., García-Manteiga, J. M., Tascini, A. S., Piella, S. N., Tikhomirov, R., Voellenkle, C., Gaetano, C., Leszek, P., Castelvecchio, S., et al. (2023) · Cells · doi:10.3390/cells12212578 · Cited by 35
HSPA12A acts as a scaffolding protein to inhibit cardiac fibroblast activation and cardiac fibrosis
Mao, Q., Zhang, X., Yang, J., Kong, Q., Cheng, H., Yu, W., Cao, X., Li, Y., Li, C., Liu, L., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.012 · Cited by 33
Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology
Liu, S., Sun, C., Tang, H., Peng, C. Y., & Peng, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1428406 · Cited by 35
“CF refers to a pathological change in which extracellular matrix (ECM) proteins are deposited and cardiac interstitial dilated (Frangogiannis, 2021), which leads to the accumulation of scar tissue, a decrease in myocardial elasticity, and the in fl uence of cardiac output, eventually arousing…”
BackgroundCD206 + IL-4Rα + Macrophages Are Drivers of Adverse Cardiac Remodeling in Ischemic Cardiomyopathy
Wang, Q., Ismahil, M. A., Zhu, Y., Rokosh, G. D., Hamid, T., Zhou, G., Pogwizd, S. M., & Prabhu, S. D. (2025) · Circulation · doi:10.1161/circulationaha.124.072411 · Cited by 37
Suppression of NADPH oxidase 4 inhibits PM2.5-induced cardiac fibrosis through ROS-P38 MAPK pathway
Wu, M., Xing, Q., Duan, H., Qin, G., & Sang, N. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155558 · Cited by 33
Vitorino, T. R., do Prado, A. F., Cáu, S. B. D. A., & Rizzi, É. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115684 · Cited by 35
WTAP boosts lipid oxidation and induces diabetic cardiac fibrosis by enhancing AR methylation
Song, K., Sun, H., Tu, B., Zhou, Y., Lin, L.-C., Liu, Z., Li, R., Yang, J., Zhang, Y., Zhao, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107931 · Cited by 34
Howard, Z. M., Dorn, L. E., Lowe, J., Gertzen, M. D., Ciccone, P., Rastogi, N., Odom, G. L., Accornero, F., Chamberlain, J. S., & Rafael‐Fortney, J. A. (2021) · JCI Insight · doi:10.1172/jci.insight.146511 · Cited by 34
Luo, H., Fu, L., Wang, X., Xu, Y., Tao, L., & Shen, X. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00868-9 · Cited by 32
Therapeutic potential of Angelica sinensis in addressing organ fibrosis: A comprehensive review
Zhi, X., Ren, C., Li, Q., Xi, H., Li, D., Chen, Q., Lv, X., Gao, X., Wu, X. S., Wang, C., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116429 · Cited by 32
Ji, D., Jin, S., Jiang, Y., Xu, F.-Y., Fan, S.-W., Zhao, Y.-L., Liu, X.-Q., Sun, H., Cheng, W.-Z., Zhang, X., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01296-7 · Cited by 35
BRD4: an effective target for organ fibrosis
Wei, Q., Gan, C., Sun, M., Xie, Y., Liu, H., Xue, T., Deng, C., Mo, C., & Ye, T. (2024) · Biomarker Research · doi:10.1186/s40364-024-00641-6 · Cited by 34
“Myofibroblasts continuously secrete extracellular matrix (ECM), such as α-smooth muscle actin (α-SMA), collagen I (COL I), and fibronectin (FN), which leads to the development of organ fibrosis [7, 67–70] of P-TEFb to HEXIM1 and converts P-TEFb to its active form [98–101].”
BackgroundUbiquitin proteasome system in cardiac fibrosis
Zeng, L., Zhang, X., Huang, Z., Song, S., Li, M., Wang, T., Sun, A., & Ge, J. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.006 · Cited by 34
Cold and hot fibrosis define clinically distinct cardiac pathologies
Miyara, S., Adler, M., Umansky, K. B., Häußler, D., Bassat, E., Divinsky, Y., Elkahal, J., Kain, D., Lendengolts, D., Flores, R. O. R., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101198 · Cited by 37
Fang, C., Zeng, Z., Ni, B., Wen, X., Fang, Z., Zou, J., & Zhang, G. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1681875 · Cited by 35
“Disrupted MMPs/TIMPs ratios promote aberrant ECM degradation, compromising tissue integrity (Frangogiannis, 2021; Bonnans, Chou, and Werb, 2014).”
The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis
Fan, J., Ren, M., Adhikari, B. K., Wang, H., & He, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s370483 · Cited by 34
“It leads to abnormalities in cardiac function and metabolism and is commonly seen at the end-stage of several cardiovascular diseases.(2,3,39) Cardiac fibrosis results from both the differentiation of cardiac fibroblasts and excessive accumulation of extracellular matrix (ECM), leading to myocardial stiffness and redu…”
BackgroundDynamic and static biomechanical traits of cardiac fibrosis
Liu, H., Fan, P., Jin, F., Huang, G., Guo, X., & Xu, F. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1042030 · Cited by 37
“…there exist a few reviews on cardiac fibrosis from the aspect of cell biological mechanisms, molecular pathways and therapeutic opportunities (Frangogiannis, 2019a; Park et al., 2019; Frangogiannis, 2021), there is still a lack of one focusing on the biomechanical properties of cardiac fibrosis.”
BackgroundMechanism of YY1 mediating autophagy dependent ferroptosis in PM2.5 induced cardiac fibrosis
Hu, H., Li, L., Zhang, H., Zhang, Y., Liu, Q., Chen, M., Ning, J., Pang, Y., Hu, W., Niu, Y., et al. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.137749 · Cited by 32
Lugrin, J., Parapanov, R., Milano, G., Cavin, S., Debonneville, A., Krueger, T., & Liaudet, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-30662-4 · Cited by 34
Guo, A. H., Baliira, R. K., Skinner, M. E., Kumar, S., Andren, A. C., Zhang, L., Goldsmith, R. S., Michán, S., Davis, N. J., Maccani, M. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16506-7 · Cited by 35
“In contrast, the WT sham to TAC comparison showed the greatest number of significantly different metabolites (44), followed by the SIRT5OE sham to TAC comparison (25).”
Zhang, G., Han, X., Xu, T., Liu, M., Chen, G., Xie, L., Xu, H., Hua, Y., Pang, M., Hu, C., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117388 · Cited by 31
Cardiac fibrogenesis: an immuno-metabolic perspective
Hoque, M. M., Gbadegoye, J. O., Hassan, F. O., Raafat, A., & Lebeche, D. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1336551 · Cited by 33
“Myocardial fi brosis is a common pathophysiologic companion of many different myocardial conditions, where the cardiac interstitium expands through the deposition of extracellular matrix (ECM) proteins (Frangogiannis, 2021) .”
BackgroundMIAT, a potent CVD-promoting lncRNA
Yang, C., Zhang, Y., & Yang, B. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04046-8 · Cited by 33
MicroRNA Roles in Cell Reprogramming Mechanisms
Pascale, E., Caiazza, C., Paladino, M., Parisi, S., Passaro, F., & Caiazzo, M. (2022) · Cells · doi:10.3390/cells11060940 · Cited by 32
Bachmann, J. C., Baumgart, S. J., Uryga, A., Bosteen, M. H., Borghetti, G., Nyberg, M., & Herum, K. M. (2022) · Cells · doi:10.3390/cells11101657 · Cited by 31
“Additionally, TGF-β has been shown to regulate the conversion of CFs to myofibroblasts by increasing αSMA expression and incorporation into stress fibres [77].”
BackgroundInfluentialFibroblast and Immune Cell Cross-Talk in Cardiac Fibrosis
Hara, A., & Tallquist, M. D. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01877-8 · Cited by 32
Cell-cell interactions in the heart: advanced cardiac models and omics technologies
Tan, S., Yang, J., Hu, S., & Lei, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03982-z · Cited by 30
“This promotes fibroblast proliferation & survival, myofibro-blast transformation, and ECM synthesis [44].”
BackgroundMosaic loss of Y chromosome and mortality after coronary angiography
Weyrich, M., Zewinger, S., Sarakpi, T., Rasper, T., Kleber, M. E., Cremer, S., Zanders, L., Fleck, F., Siegbahn, A. G., Wallentin, L. C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf035 · Cited by 30
SGLT2 inhibitors and cardiac fibrosis: A comprehensive review
Karakasis, P., Theofilis, P., Vlachakis, P. K., Apostolos, A., Milaras, N., Ktenopoulos, N., Grigoriou, K., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., et al. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103149 · Cited by 30
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.